SG10201500161XA - Modified rsv f proteins and methods of their use - Google Patents
Modified rsv f proteins and methods of their useInfo
- Publication number
- SG10201500161XA SG10201500161XA SG10201500161XA SG10201500161XA SG10201500161XA SG 10201500161X A SG10201500161X A SG 10201500161XA SG 10201500161X A SG10201500161X A SG 10201500161XA SG 10201500161X A SG10201500161X A SG 10201500161XA SG 10201500161X A SG10201500161X A SG 10201500161XA
- Authority
- SG
- Singapore
- Prior art keywords
- proteins
- methods
- modified rsv
- rsv
- modified
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12112608P | 2008-12-09 | 2008-12-09 | |
US16907709P | 2009-04-14 | 2009-04-14 | |
US22478709P | 2009-07-10 | 2009-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201500161XA true SG10201500161XA (en) | 2015-03-30 |
Family
ID=42310119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011041696A SG172022A1 (en) | 2008-12-09 | 2009-12-09 | Modified rsv f proteins and methods of their use |
SG10201500161XA SG10201500161XA (en) | 2008-12-09 | 2009-12-09 | Modified rsv f proteins and methods of their use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011041696A SG172022A1 (en) | 2008-12-09 | 2009-12-09 | Modified rsv f proteins and methods of their use |
Country Status (23)
Country | Link |
---|---|
US (7) | US8715692B2 (pl) |
EP (3) | EP3718566A1 (pl) |
JP (4) | JP5813513B2 (pl) |
KR (2) | KR101691574B1 (pl) |
CN (2) | CN102307591B (pl) |
AU (1) | AU2009333484B2 (pl) |
BR (1) | BRPI0922867B8 (pl) |
CA (1) | CA2746228C (pl) |
CY (2) | CY1117757T1 (pl) |
DK (2) | DK2370099T3 (pl) |
ES (2) | ES2796725T3 (pl) |
HK (1) | HK1161690A1 (pl) |
HR (2) | HRP20160859T1 (pl) |
HU (2) | HUE051666T2 (pl) |
IL (2) | IL213450B (pl) |
LT (1) | LT3067064T (pl) |
MX (4) | MX337932B (pl) |
PL (2) | PL3067064T3 (pl) |
PT (2) | PT2370099T (pl) |
RU (1) | RU2531510C2 (pl) |
SG (2) | SG172022A1 (pl) |
SI (2) | SI3067064T1 (pl) |
WO (1) | WO2010077717A1 (pl) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160000902A1 (en) * | 2003-07-11 | 2016-01-07 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
AU2009316680B2 (en) * | 2008-11-18 | 2016-03-24 | Takeda Vaccines, Inc. | RSV F VLPs and methods of manufacture and use thereof |
CN102307591B (zh) | 2008-12-09 | 2016-08-03 | 诺瓦瓦克斯股份有限公司 | 修饰的rsv f蛋白及其使用方法 |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
EP4218799A1 (en) * | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
US20110097358A1 (en) * | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
DK2635257T3 (en) * | 2010-11-05 | 2017-09-04 | Novavax Inc | Rabies virus-like glycoprotein particles (VLP) |
WO2012089231A1 (en) * | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
US10342862B2 (en) | 2011-01-26 | 2019-07-09 | Glaxosmithkline Biologicals, Sa | RSV immunization regimen |
WO2013019800A1 (en) * | 2011-08-01 | 2013-02-07 | Emory University | Vlps containing ligands and methods related thereto |
EP2752199A4 (en) | 2011-08-29 | 2015-04-29 | Univ Tokushima | RSV MUCOSA VACCINE |
CA2849471A1 (en) * | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
CN103239734B (zh) * | 2012-02-10 | 2016-02-24 | 北京艾棣维欣生物技术有限公司 | 用于预防和/或治疗呼吸道合胞病毒感染的疫苗 |
EA201891945A3 (ru) | 2012-08-01 | 2019-05-31 | Бавариан Нордик А/С | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) |
MX2015006377A (es) | 2012-11-20 | 2015-07-21 | Glaxosmithkline Biolog Sa | Trimeros prefusion de f de vsr. |
AU2014214590A1 (en) * | 2013-02-11 | 2015-08-27 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
DE102013004595A1 (de) * | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
WO2015042373A1 (en) | 2013-09-19 | 2015-03-26 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
US10100372B2 (en) | 2014-06-18 | 2018-10-16 | Georgia State University Research Foundation, Inc. | Recombinant RSV reporter virus |
US9969986B2 (en) * | 2014-08-08 | 2018-05-15 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
RU2730625C2 (ru) | 2015-09-03 | 2020-08-24 | Новавакс, Инк. | Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью |
RU2723039C2 (ru) | 2015-12-23 | 2020-06-08 | Пфайзер Инк. | Мутанты белка f rsv |
KR102401247B1 (ko) | 2016-04-05 | 2022-05-25 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
MX2018014699A (es) | 2016-05-30 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
CN106011086A (zh) * | 2016-06-15 | 2016-10-12 | 湖北省农业科学院畜牧兽医研究所 | 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法 |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
KR20190135017A (ko) * | 2017-03-30 | 2019-12-05 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
US11192926B2 (en) | 2017-04-04 | 2021-12-07 | University Of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use |
RU2019142012A (ru) | 2017-06-14 | 2021-07-14 | Вирометикс Аг | Циклические пептиды для защиты от респираторно-синцитиального вируса |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
CA3095216A1 (en) | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
KR20210004959A (ko) | 2018-03-19 | 2021-01-13 | 노바백스, 인코포레이티드 | 다가 인플루엔자 나노입자 백신 |
EP3775174A4 (en) * | 2018-03-30 | 2022-07-06 | Georgia State University Research Foundation, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES |
KR20200050264A (ko) | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
AU2019408048A1 (en) | 2018-12-20 | 2021-06-24 | Universität Zürich | Lipopeptide building blocks and synthetic virus-like particles |
WO2020175660A1 (ja) | 2019-02-28 | 2020-09-03 | Kmバイオロジクス株式会社 | Rsv f/gキメラワクチン |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
IL295142A (en) * | 2020-01-27 | 2022-09-01 | Novavax Inc | Formulations for the vaccine against the corona virus |
GB2594365B (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
CN113855796B (zh) * | 2021-07-30 | 2024-01-26 | 河北医科大学 | 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用 |
WO2023062651A1 (en) * | 2021-10-13 | 2023-04-20 | Padmanabh Patil Harshad | Virus-like particles for respiratory syncytial virus and method of preparation thereof |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
GB8914968D0 (en) * | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
CA2399321C (en) | 2000-03-07 | 2013-04-30 | Robert K. Evans | Adenovirus formulations |
MXPA03002890A (es) | 2000-10-02 | 2004-12-03 | Glaxosmithkline Biolog Sa | Preparacion de virus con envolvente dividido. |
AU2003219760A1 (en) | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
KR101187955B1 (ko) | 2003-04-25 | 2012-10-08 | 비로노바티브 비브이 | 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합파라인플루엔자 바이러스 발현 시스템 및 백신 |
US8541003B2 (en) * | 2003-06-20 | 2013-09-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
EP1713824A2 (en) | 2003-12-10 | 2006-10-25 | The Uab Research Foundation | Recombinant viruses with heterologous envelope proteins |
WO2006099360A2 (en) | 2005-03-10 | 2006-09-21 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
CA2655929A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
EP2089515A4 (en) * | 2006-11-16 | 2011-02-23 | Novavax Inc | VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS |
US8772256B2 (en) * | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
EP1972348A1 (en) * | 2007-03-14 | 2008-09-24 | Pierre Fabre Medicament | Novel vaccine composition for the treatment of respiratory infectious diseases |
EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
PL2540312T3 (pl) | 2007-07-19 | 2015-10-30 | Novavax Inc | Chimeryczne VLP ptasiej grypy |
DK2222710T3 (en) | 2007-12-24 | 2016-10-03 | Id Biomedical Corp Quebec | Recombinant RSV antigens. |
EP2254554A1 (en) | 2008-02-25 | 2010-12-01 | Novavax, Inc. | Sugar glassified virus like particles (vlps) |
CN102307591B (zh) | 2008-12-09 | 2016-08-03 | 诺瓦瓦克斯股份有限公司 | 修饰的rsv f蛋白及其使用方法 |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
WO2010138192A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
PE20121541A1 (es) * | 2009-06-24 | 2012-12-21 | Glaxosmithkline Biolog Sa | Antigenos de virus de sincicio respiratorio recombinantes |
EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
DK2635257T3 (en) | 2010-11-05 | 2017-09-04 | Novavax Inc | Rabies virus-like glycoprotein particles (VLP) |
JP2014520807A (ja) * | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | 免疫原性組成物およびその使用 |
CA2849471A1 (en) | 2011-09-30 | 2013-04-04 | Novavax, Inc. | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
AU2014214590A1 (en) | 2013-02-11 | 2015-08-27 | Novavax, Inc. | Combination vaccine for respiratory syncytial virus and influenza |
AP2015008815A0 (en) | 2013-04-25 | 2015-10-31 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
AU2014100888A4 (en) | 2014-08-07 | 2014-09-11 | Novartis Ag | Virus clearance and protein purification methods |
WO2017000105A1 (zh) * | 2015-06-29 | 2017-01-05 | 尚平 | 便携式加湿器 |
RU2730625C2 (ru) | 2015-09-03 | 2020-08-24 | Новавакс, Инк. | Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью |
-
2009
- 2009-12-09 CN CN200980156344.9A patent/CN102307591B/zh active Active
- 2009-12-09 MX MX2014011966A patent/MX337932B/es unknown
- 2009-12-09 US US12/633,995 patent/US8715692B2/en active Active
- 2009-12-09 LT LTEP16166033.7T patent/LT3067064T/lt unknown
- 2009-12-09 HU HUE16166033A patent/HUE051666T2/hu unknown
- 2009-12-09 MX MX2016003771A patent/MX345700B/es unknown
- 2009-12-09 SG SG2011041696A patent/SG172022A1/en unknown
- 2009-12-09 PT PT98367519T patent/PT2370099T/pt unknown
- 2009-12-09 EP EP20171841.8A patent/EP3718566A1/en active Pending
- 2009-12-09 DK DK09836751.9T patent/DK2370099T3/en active
- 2009-12-09 SI SI200932062T patent/SI3067064T1/sl unknown
- 2009-12-09 BR BRPI0922867A patent/BRPI0922867B8/pt active IP Right Grant
- 2009-12-09 MX MX2017001924A patent/MX358836B/es unknown
- 2009-12-09 KR KR1020117015954A patent/KR101691574B1/ko active IP Right Grant
- 2009-12-09 MX MX2011006205A patent/MX2011006205A/es active IP Right Grant
- 2009-12-09 PL PL16166033T patent/PL3067064T3/pl unknown
- 2009-12-09 CA CA2746228A patent/CA2746228C/en active Active
- 2009-12-09 PT PT161660337T patent/PT3067064T/pt unknown
- 2009-12-09 PL PL09836751.9T patent/PL2370099T3/pl unknown
- 2009-12-09 AU AU2009333484A patent/AU2009333484B2/en active Active
- 2009-12-09 EP EP09836751.9A patent/EP2370099B1/en active Active
- 2009-12-09 SI SI200931470A patent/SI2370099T1/sl unknown
- 2009-12-09 DK DK16166033.7T patent/DK3067064T3/da active
- 2009-12-09 SG SG10201500161XA patent/SG10201500161XA/en unknown
- 2009-12-09 ES ES16166033T patent/ES2796725T3/es active Active
- 2009-12-09 RU RU2011128371/10A patent/RU2531510C2/ru active
- 2009-12-09 EP EP16166033.7A patent/EP3067064B1/en active Active
- 2009-12-09 KR KR1020167035029A patent/KR101801213B1/ko active IP Right Grant
- 2009-12-09 HU HUE09836751A patent/HUE029037T2/en unknown
- 2009-12-09 CN CN201610520252.6A patent/CN106146671B/zh active Active
- 2009-12-09 WO PCT/US2009/067269 patent/WO2010077717A1/en active Application Filing
- 2009-12-09 ES ES09836751.9T patent/ES2582005T3/es active Active
- 2009-12-09 JP JP2011540854A patent/JP5813513B2/ja active Active
-
2011
- 2011-06-09 IL IL213450A patent/IL213450B/en active IP Right Grant
-
2012
- 2012-03-06 HK HK12102267.8A patent/HK1161690A1/zh unknown
-
2014
- 2014-03-21 US US14/221,675 patent/US9675685B2/en active Active
-
2015
- 2015-06-04 US US14/730,805 patent/US9731000B2/en active Active
- 2015-06-04 US US14/730,809 patent/US9717786B2/en active Active
- 2015-06-19 JP JP2015124158A patent/JP6162751B2/ja active Active
- 2015-08-28 US US14/839,247 patent/US10022437B2/en active Active
-
2016
- 2016-07-11 CY CY20161100652T patent/CY1117757T1/el unknown
- 2016-07-13 HR HRP20160859TT patent/HRP20160859T1/hr unknown
- 2016-08-18 IL IL247341A patent/IL247341B/en active IP Right Grant
-
2017
- 2017-06-15 JP JP2017118032A patent/JP6462048B2/ja active Active
-
2018
- 2018-06-15 US US16/009,257 patent/US11052146B2/en active Active
- 2018-12-26 JP JP2018242108A patent/JP6782289B2/ja active Active
-
2020
- 2020-05-29 CY CY20201100490T patent/CY1123152T1/el unknown
- 2020-06-02 HR HRP20200871TT patent/HRP20200871T1/hr unknown
-
2022
- 2022-08-10 US US17/818,887 patent/US20230293667A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160859T1 (hr) | Modificirani proteini rsv f i postupci njihove upotrebe | |
IL248723B (en) | Specific antibodies against the bcr complex and methods of using them | |
LT2373691T (lt) | Anti-fxi antikūnai ir jų panaudojimo būdai | |
EP2373679A4 (en) | HEPPIDINE MINI PEPTIDES AND METHODS OF USE | |
HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
EP2367844A4 (en) | RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
EP2185719A4 (en) | RANTES ANTIBODIES AND METHOD FOR THEIR USE | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
IL206125A0 (en) | Azaindolizines and methods of use | |
EP2346521A4 (en) | PEPTIDES AND METHODS OF USE | |
ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
IL213749A0 (en) | Dgati nucleic acids and proteins and methods of use thereof | |
ZA201007681B (en) | Cd4-related polypeptides and methods of use | |
EP2265117A4 (en) | INHIBITORS OF PROTEIN PHOSPHATASE-1 AND USES THEREOF |